TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > Our Services > ANDA Withdrawals

ANDA Withdrawals

Don’t risk withdrawal of your ANDA by FDA!

An Abbreviated New Drug Application (ANDA) is an application for US generic drug approval for an existing licensed medication or approved drug. According to Guidance for Industry – Changes to an Approved NDA or ANDA, any changes to an approved ANDA or New Drug Application (NDA) must be reported to the FDA.

  • Major change: Prior Approval Supplement (PAS, approval required)
  • Moderate change: Supplement – Changes Being Effected in 30 Days (CBE-30, “tell, wait & do”)
  • (Moderate change: Supplement – Changes Being Effected (CBE-0, “tell & do & may cease”)
  • Minor change: Annual Report (“do & tell”)

Code of Federal Regulations 21 CFR 314.81 requires an applicant to submit an annual report for every approved NDA and every ANDA. If not done: FDA may withdraw your NDA / ANDA

The US Food and Drug Administration (FDA) announced in early 2020 that it plans to withdraw the approval of 249 Abbreviated New Drug Applications (ANDAs) after their manufacturers repeatedly failed to submit annual reports for their generic drugs.

FDA Code of Federal Regulations (21 CFR 314.81) requires that all ANDA / NDA-holders must submit an annual report for each approved marketing application – if this is not done the FDA may rescind your NDA / ANDA approval. Accordingly, the FDA maintains that manufacturers will have the opportunity to request a hearing to appeal the decision by filing a written request and providing the agency with a rationale for why the ANDA should not be withdrawn.

Want to find out more?

PharmaLex. Confidence beyond compliance.

Contact us for more information

PharmaLex assists in halting an FDA withdrawal process and goes beyond by:

  • Ensuring regulatory compliance for your supplements and annual reports
  • Supplements & annual reports
    • Health authority contact
    • Classification and categorization
    • Prepare submission strategy for US (and worldwide)
    • If applicable, align global implementation strategy, including compilation, submission and follow-up procedures
    • FDA gateway submission and tracking
    • Technical authoring of content
    • CMC writing services: compilation of quality dossiers (M3 and M2.3)
    • Product Information Management and labeling/SPL
  • Regulatory expertise on a daily basis
    • Providing US and global regulatory strategy and intelligence
    • Provide regulatory expertise and support to all functions within client company (manufacturing site, quality, pharmacovigilance, etc)
    • Gap analysis, global roll out strategies, change control review
    • Fill in with experienced regulatory staff for staff shortages, maternity leaves, medical leaves, etc.
  • Extend compliance by taking full regulatory responsibility for parts of your portfolio
  • All maintenance activities (REG submissions, CMC, labeling, data capture, …) handled by PharmaLex on a global and / or country level, with interfaces to different customer functions such as marketing, local affiliates, manufacturing sites and medical affairs as well as national regulatory authorities
  • Program governance structure with clear roles and responsibilities
    • Product teams with experts and interfaces to client
    • Program manager for strategic discussions
    • Upper management steering committee and decision board for strategic decisions
  • Controlling and performance measurement via defined budget & KPIs
  • Flexible staffing to meet arising project needs
  • Ensure project continuity with backup staff to manage peak workload activities (“Breathing Organization”)
  • Not necessarily one-to one staffing of client roles to gain efficiencies
  • “Breathing Organization” – Up-scaling and down-scaling of teams as needed

Continuous process consultancy and operative innovations are part of the program

Related News

Better information, better decisions for your access strategy – Inmediata powered by SmartPHLEX a new platform
Better information, better decisions for your access strategy – Inmediata powered by SmartPHLEX a new platform
26th May 2022
PharmaLex broadens market access and HEOR reach
PharmaLex broadens market access and HEOR reach
4th June 2021
Alternative Pathways for Medical Device Market Authorisation
Alternative Pathways for Medical Device Market Authorisation
29th April 2021

Related Resources

Fact Flyers

  • Real World Evidence

Webinars

  • Healthcare system resilience during and after the pandemic
  • Early-Phase Modelling – Costs and Effectiveness in Pharma

Infographics

  • Early Phase Modeling

Related Services

  • Healthcare Compliance and Medical Approval
  • Market Access

What our clients say

Pharmalex provided the resources we needed to compile Investigational Medicinal Product Dossiers for our biological products. The dossiers were delivered on time with the trusted quality we expected

Small US Biopharmaceutical Company
Sr Director Regulatory Affairs CMC

During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.

Large Pharma, Germany
VP Regulatory Affairs
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
8 Jun

Mark A Lane, PhD latest blog here https://lnkd.in/ejDdywz3 explores Integrated Product Development approaches to accelerate drug development.

To find out more register for our IPD webinar https://lnkd.in/eijUBJM5

#pharmadrugdevelopment
#webinar
#biopharmaceutical

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Our project team were very impressed with the quality of the research and the reports that you sent through. We didn’t need any convincing that your recommendations should be followed. It showed PharmaLex in a very positive light, and the Project Team are keen to work with you again.

    Leading European Specialist Pharma Company
    Head of Medical Writing and Publications
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for